热门资讯> 正文

NewAmsterdam Pharma报告财年业绩

2026-02-19 04:25

NewAmsterdam Pharma press release (NAMS): FY Revenue of $22.5M.
Net loss for the year ended December 31, 2025, was $203.8 million, compared to net loss of $241.6 million in the year ended December 31, 2024.
As of December 31, 2025, NewAmsterdam reported cash, cash equivalents and marketable securities of $728.9 million, compared to $834.2 million as of December 31, 2024.

More on NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Seeking Alpha’s Quant Rating on NewAmsterdam Pharma
Historical earnings data for NewAmsterdam Pharma
Financial information for NewAmsterdam Pharma

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。